611
Small moleculeexperimental
Clinical trial activity
5 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
3
Phase 2
4
Phase 3
0
Phase 4
0
Earliest trial started Oct 18, 2021 (NCT05641558)
Timeline
Indications
Mechanism of action
- UnclearUnclear
Unclear unclear
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07042113 | Phase 1 | Jul 31, 2025 | Sunshine Lake Pharma Co., Ltd. |
| NCT06324812 | Phase 1/Phase 2 (Phase 2) | Mar 31, 2024 | Capital Medical University, Sunshine Lake Pharma Co., Ltd. |
| NCT06099652 | Phase 2 | Nov 30, 2023 | Sunshine Lake Pharma Co., Ltd. |
| NCT05544591 | Phase 2 | Oct 26, 2022 | Sunshine Lake Pharma Co., Ltd. |
| NCT05641558 | Phase 1/Phase 2 (Phase 2) | Oct 18, 2021 | China Medical University, Sunshine Lake Pharma Co., Ltd. |
Showing 5 of 5 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Sunshine Lake Pharma Co., Ltd. | For profit | 5 | 5 | 2 | 2021 |
| Capital Medical University | Academic/Hospital | 1 | 0 | 1 | 2024 |
| China Medical University | Academic/Hospital | 1 | 0 | 1 | 2021 |
3 organizations
Page 1 / 1